BofA analyst Tim Anderson raised the firm’s price target on Merck (MRK) to $105 from $98 and keeps a Buy rating on the shares. The Cidara (CDTX) deal is a “reasonable” one, as the company’s experimental flu drug is a novel asset with a high likelihood of technical success and complementary to Merck’s Infectious Disease franchise, the analyst tells investors in a research note. The firm added that Merck shares are too cheap for the growth it should be able to deliver on a near- and long-term basis.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Merck expects over $5B opportunity from Cidara’s flu drug, Reuters reports
- Hold Rating on Merck & Company: Balancing Strategic Acquisitions and Future Growth Prospects
- Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
- Eli Lilly, GM, IonQ, Merck, MARA: Insider Moves Unveiled!
- Midday Fly By: Walmart names new CEO, Merck acquires Cidara